CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-30 | Burrows Scott L Chief Financial Officer | Option exercise 10b5-1 | +17,500 | $14.50 | $254K | 97,262 |
| 2026-09-30 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −17,500 | $89.89 | $1.6M | 79,762 |
| 2026-09-30 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −17,500 | 319,857 | ||
| 2026-09-02 | King-Jones Heidy See Remarks | Option exercise 10b5-1 | +400 | $14.50 | $6K | 3,245 |
| 2026-09-02 | King-Jones Heidy See Remarks | Sale 10b5-1 | −400 | $90.00 | $36K | 2,845 |
| 2026-09-02 | King-Jones Heidy See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −400 | 511,411 | ||
| 2026-09-02 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −18,232 | $89.35 | $1.6M | 79,762 |
| 2026-09-01 | King-Jones Heidy See Remarks | Option exercise 10b5-1 | +27,999 | $14.50 | $406K | 30,844 |
| 2026-09-01 | King-Jones Heidy See Remarks | Sale 10b5-1 | −4,845 | $86.40 | $419K | 25,999 |
| 2026-09-01 | King-Jones Heidy See Remarks | Sale 10b5-1 | −16,548 | $87.20 | $1.4M | 9,451 |
| 2026-09-01 | King-Jones Heidy See Remarks | Sale 10b5-1 | −6,206 | $88.17 | $547K | 3,245 |
| 2026-09-01 | King-Jones Heidy See Remarks | Sale 10b5-1 | −400 | $89.38 | $36K | 2,845 |
| 2026-09-01 | King-Jones Heidy See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,999 | 511,811 | ||
| 2026-09-01 | Burrows Scott L Chief Financial Officer | Option exercise 10b5-1 | +7,500 | $14.50 | $109K | 105,494 |
| 2026-09-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −900 | $86.25 | $78K | 104,594 |
| 2026-09-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −4,384 | $87.11 | $382K | 100,210 |
| 2026-09-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −2,016 | $88.03 | $177K | 98,194 |
| 2026-09-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −200 | $89.04 | $18K | 97,994 |
| 2026-09-01 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 337,357 | ||
| 2026-09-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −2,500 | $86.36 | $216K | 565,040 |
Page 2 of 11 · 213 trades